The CCN family of proteins: structure-function relationships

Trends in Biochemical Sciences

Volumn 33, Issue 10, 2008, Pages 461-473

  Holbourn, Kenneth P ^a   Acharya, K Ravi ^a   Perbal, Bernard ^b,c  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^c Research and Development   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CYSTEINE; CYSTEINE RICH PROTEIN 61; LIGAND; THROMBOSPONDIN 1; VON WILLEBRAND FACTOR;

ANGIOGENESIS; BONE DEVELOPMENT; CARCINOGENESIS; CELL ADHESION; CELL PROLIFERATION; CHONDROGENESIS; EXON; EXTRACELLULAR MATRIX; MOLECULAR BIOLOGY; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; STRUCTURE ACTIVITY RELATION; WOUND HEALING;

EID: 53149092430     PISSN: 09680004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tibs.2008.07.006     Document Type: Review

References (107)

1. Bork P. The modular architecture of a new family of growth regulators related to connective tissue growth factor. FEBS Lett. 327 (1993) 125-130
2. Brigstock D.R., et al. Proposal for a unified CCN nomenclature. Mol. Pathol. 56 (2003) 127-128
3. Lau L.F., and Lam S.C. The CCN family of angiogenic regulators: the integrin connection. Exp. Cell Res. 248 (1999) 44-57
4. Brigstock D.R. The connective tissue growth factor/cysteine-rich 61/nephroblastoma overexpressed (CCN) family. Endocr. Rev. 20 (1999) 189-206
5. Perbal B. The CCN family of genes: a brief history. Mol. Pathol. 54 (2001) 103-104
6. Perbal B., and Takigawa M. CCN Proteins: A New Family of Cell Growth and Differentiation Regulators. 1st Edn (2005), Imperial College Press
7. Perbal B. CCN proteins: multifunctional signalling regulators. Lancet 363 (2004) 62-64
8. Brigstock D.R. The CCN family: a new stimulus package. J. Endocrinol. 178 (2003) 169-175
9. Bornstein P. Diversity of function is inherent in matricellular proteins: an appraisal of thrombospondin 1. J. Cell Biol. 130 (1995) 503-506
10. Grotendorst G., and Duncan M. Individual domains of connective tissue growth factor regulate fibroblast proliferation and myofibroblast differentiation. FASEB J. 19 (2005) 729-738
11. Perbal B. NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues. Mol. Pathol. 54 (2001) 57-79
12. Leask A., and Abraham D.J. All in the CCN family: essential matricellular signaling modulators emerge from the bunker. J. Cell Sci. 119 (2006) 4803-4810
13. Fukunaga-Kalabis M., et al. CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J. Cell Biol. 175 (2006) 563-569
14. Grotendorst G.R. Connective tissue growth factor: a mediator of TGF-beta action on fibroblasts. Cytokine Growth Factor Rev. 8 (1997) 171-179
15. Mori Y., et al. Connective tissue growth factor/CCN2-null mouse embryonic fibroblasts retain intact transforming growth factor-beta responsiveness. Exp. Cell Res. 314 (2008) 1094-1104
16. Thiery J.P. Cell adhesion in development: a complex signaling network. Curr. Opin. Genet. Dev. 13 (2003) 365-371
17. Kubota S., and Takigawa M. CCN family proteins and angiogenesis: from embryo to adulthood. Angiogenesis 10 (2007) 1-11
18. Parisi M.S., et al. Expression and regulation of CCN genes in murine osteoblasts. Bone 38 (2006) 671-677
19. Pala D., et al. Focal adhesion kinase/Src suppresses early chondrogenesis: central role of CCN2. J. Biol. Chem. 283 (2008) 9239-9247
20. Lin C.G., et al. CCN3 (NOV) is a novel angiogenic regulator of the CCN protein family. J. Biol. Chem. 278 (2003) 24200-24208
21. Nathans D., et al. Genomic response to growth factors. Cold Spring Harb. Symp. Quant. Biol. 53 (1988) 893-900
22. Schafer M., and Werner S. Transcriptional control of wound repair. Annu. Rev. Cell Dev. Biol. 23 (2007) 69-92
23. Rachfal A.W., and Brigstock D.R. Structural and functional properties of CCN proteins. Vitam. Horm. 70 (2005) 69-103
24. Bleau A.M., et al. Antiproliferative activity of CCN3: involvement of the C-terminal module and post-translational regulation. J. Cell. Biochem. 101 (2007) 1475-1491
25. Yosimichi G., et al. CTGF/Hcs24 induces chondrocyte differentiation through a p38 mitogen-activated protein kinase (p38MAPK), and proliferation through a p44/42 MAPK/extracellular-signal regulated kinase (ERK). Eur. J. Biochem. 268 (2001) 6058-6065
26. Baguma-Nibasheka M., and Kablar B. Pulmonary hypoplasia in the connective tissue growth factor (Ctgf) null mouse. Dev. Dyn. 237 (2008) 485-493
27. Kennedy L., et al. CCN2 is necessary for the function of mouse embryonic fibroblasts. Exp. Cell Res. 313 (2007) 952-964
28. Kubota S., et al. Multiple activation of mitogen-activated protein kinases by purified independent CCN2 modules in vascular endothelial cells and chondrocytes in culture. Biochimie 88 (2006) 1973-1981
29. Bleau A.M., et al. CCN proteins and cancer: two to tango. Front. Biosci. 10 (2005) 998-1009
30. Perbal B. The CCN3 protein and cancer. Adv. Exp. Med. Biol. 587 (2006) 23-40
31. Kleer C.G., et al. CCN6 (WISP3) as a new regulator of the epithelial phenotype in breast cancer. Cells Tissues Organs 185 (2007) 95-99
32. Perbal B., et al. Antiproliferative activity of CCN3: qualitative and quantitative aspects. J. Cell Commun. Sig. 1 (2007) 69
33. Kubota S., et al. Report on the fourth international workshop on the CCN family of genes. J. Cell. Commun. Sig. 1 (2007) 59-65
34. Katsuki Y., et al. Inhibitory effect of CT domain of CCN3/NOV on proliferation and differentiation of osteogenic mesenchymal stem cells, Kusa-A1. Biochem. Biophys. Res. Commun. 368 (2008) 808-814
35. Böhlig L., et al. The CCN3 gene coding for an extracellular adhesion-related protein is transcriptionally activated by the p53 tumor suppressor. Cell Cycle 7 (2008) 1254-1261
36. Planque N., and Perbal B. A structural approach to the role of CCN (CYR61/CTGF/NOV) proteins in tumourigenesis. Cancer Cell Int. 3 (2003) 15
37. Perbal B. NOV story: the way to CCN3. Cell Commun. Signal. 4 (2006) 3
38. McCallum L., et al. A novel mechanism for BCR-ABL action: stimulated secretion of CCN3 is involved in growth and differentiation regulation. Blood 108 (2006) 1716-1723
39. Vallacchi V., et al. CCN3/nephroblastoma overexpressed matricellular protein regulates integrin expression, adhesion, and dissemination in melanoma. Cancer Res. 68 (2008) 715-723
40. Fukunaga-Kalabis M., et al. Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene 27 (2007) 2552-2560
41. Chen P.P., et al. Expression of Cyr61, CTGF, and WISP-1 correlates with clinical features of lung cancer. PLoS One 2 (2007) e534
42. Gardini A., et al. Expression of connective tissue growth factor is a prognostic marker for patients with intrahepatic cholangiocarcinoma. Dig. Liver Dis. 37 (2005) 269-274
43. Davies S.R., et al. Differential expression and prognostic implications of the CCN family members WISP-1, WISP-2, and WISP-3 in human breast cancer. Ann. Surg. Oncol. 14 (2007) 1909-1918
44. Perbal B., et al. Report on the second international workshop on the CCN family of genes. Mol. Pathol. 56 (2003) 80-85
45. Zhang Y., et al. Inhibition of CCN6 (WISP3) expression promotes neoplastic progression and enhances the effects of insulin-like growth factor-1 on breast epithelial cells. Breast Cancer Res. 7 (2005) 1080-1089
46. Manara M.C., et al. The expression of CCN3 (NOV) gene in musculoskeletal tumors. Am. J. Pathol. 160 (2002) 849-859
47. Perbal B., et al. Prognostic value of CCN3 in osteosarcoma. Clin. Cancer Res. 14 (2008) 701-709
48. Perbal B. The CCN3 (NOV) cell growth regulator: a new tool for molecular medicine. Expert Rev. Mol. Diagn. 3 (2003) 597-604
49. Hohenester E., and Engel J. Domain structure and organisation in extracellular matrix proteins. Matrix Biol. 21 (2002) 115-128
50. Jones J.I., and Clemmons D.R. Insulin-like growth factors and their binding proteins: biological actions. Endocr. Rev. 16 (1995) 3-34
51. Hwa V., et al. The insulin-like growth factor-binding protein (IGFBP) superfamily. Endocr. Rev. 20 (1999) 761-787
52. Firth S.M., and Baxter R.C. Cellular actions of the insulin-like growth factor binding proteins. Endocr. Rev. 23 (2002) 824-854
53. Kim H.S., et al. Identification of a family of low-affinity insulin-like growth factor binding proteins (IGFBPs): characterization of connective tissue growth factor as a member of the IGFBP superfamily. Proc. Natl. Acad. Sci. U. S. A. 94 (1997) 12981-12986
54. Yan X., et al. The aminoterminal insulin-like growth factor (IGF) binding domain of IGF binding protein-3 cannot be functionally substituted by the structurally homologous domain of CCN3. Endocrinology 147 (2006) 5268-5274
55. Sitar T., et al. Structural basis for the inhibition of insulin-like growth factors by insulin-like growth factor-binding proteins. Proc. Natl. Acad. Sci. U. S. A. 103 (2006) 13028-13033
56. Siwanowicz I., et al. Structural basis for the regulation of insulin-like growth factors by IGF binding proteins. Structure 13 (2005) 155-167
57. Kalus W., et al. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J. 17 (1998) 6558-6572
58. Zhang J.L., et al. von Willebrand factor type C domain-containing proteins regulate bone morphogenetic protein signaling through different recognition mechanisms. J. Biol. Chem. 282 (2007) 20002-20014
59. Abreu J.G., et al. Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat. Cell Biol. 4 (2002) 599-604
60. Mancuso D.J., et al. Structure of the gene for human von Willebrand factor. J. Biol. Chem. 264 (1989) 19514-19527
61. Zhu Y., et al. Type IIA procollagen containing the cysteine-rich amino propeptide is deposited in the extracellular matrix of prechondrogenic tissue and binds to TGF-beta1 and BMP-2. J. Cell Biol. 144 (1999) 1069-1080
62. Nakayama N., et al. A novel chordin-like protein inhibitor for bone morphogenetic proteins expressed preferentially in mesenchymal cell lineages. Dev. Biol. 232 (2001) 372-387
63. Sakuta H., et al. Ventroptin: a BMP-4 antagonist expressed in a double-gradient pattern in the retina. Science 293 (2001) 111-115
64. Hogan B.L. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes Dev. 10 (1996) 1580-1594
65. Hogan B.L. Bone morphogenetic proteins in development. Curr. Opin. Genet. Dev. 6 (1996) 432-438
66. Larrain J., et al. BMP-binding modules in chordin: a model for signalling regulation in the extracellular space. Development 127 (2000) 821-830
67. Massague J. Identification of receptors for type-beta transforming growth factor. Methods Enzymol. 146 (1987) 174-195
68. Minamizato T., et al. CCN3/NOV inhibits BMP-2-induced osteoblast differentiation by interacting with BMP and Notch signaling pathways. Biochem. Biophys. Res. Commun. 354 (2007) 567-573
69. Voorberg J., et al. Assembly and routing of von Willebrand factor variants: the requirements for disulfide-linked dimerization reside within the carboxy-terminal 151 amino acids. J. Cell Biol. 113 (1991) 195-205
70. O'Leary J.M., et al. Solution structure and dynamics of a prototypical chordin-like cysteine-rich repeat (von Willebrand Factor type C module) from collagen IIA. J. Biol. Chem. 279 (2004) 53857-53866
71. Keller S., et al. Molecular recognition of BMP-2 and BMP receptor IA. Nat. Struct. Mol. Biol. 11 (2004) 481-488
72. Lawler J., and Hynes R.O. The structure of human thrombospondin, an adhesive glycoprotein with multiple calcium-binding sites and homologies with several different proteins. J. Cell Biol. 103 (1986) 1635-1648
73. Tucker R.P. The thrombospondin type 1 repeat superfamily. Int. J. Biochem. Cell Biol. 36 (2004) 969-974
74. Adams J.C., and Tucker R.P. The thrombospondin type 1 repeat (TSR) superfamily: diverse proteins with related roles in neuronal development. Dev. Dyn. 218 (2000) 280-299
75. Takagi J., et al. A single chain 19-kDa fragment from bovine thrombospondin binds to type V collagen and heparin. J. Biol. Chem. 268 (1993) 15544-15549
76. Sipes J.M., et al. Inhibition of fibronectin binding and fibronectin-mediated cell adhesion to collagen by a peptide from the second type I repeat of thrombospondin. J. Cell Biol. 121 (1993) 469-477
77. Asch A.S., et al. Thrombospondin sequence motif (CSVTCG) is responsible for CD36 binding. Biochem. Biophys. Res. Commun. 182 (1992) 1208-1217
78. Schultz-Cherry S., et al. Regulation of transforming growth factor-beta activation by discrete sequences of thrombospondin 1. J. Biol. Chem. 270 (1995) 7304-7310
79. Guo N.H., et al. Heparin-binding peptides from the type I repeats of thrombospondin. Structural requirements for heparin binding and promotion of melanoma cell adhesion and chemotaxis. J. Biol. Chem. 267 (1992) 19349-19355
80. Chen H., et al. The cell biology of thrombospondin-1. Matrix Biol. 19 (2000) 597-614
81. Holt G.D., et al. Properdin binds to sulfatide [Gal(3-SO4)beta 1-1 Cer] and has a sequence homology with other proteins that bind sulfated glycoconjugates. J. Biol. Chem. 265 (1990) 2852-2855
82. Inoki I., et al. Connective tissue growth factor binds vascular endothelial growth factor (VEGF) and inhibits VEGF-induced angiogenesis. FASEB J. 16 (2002) 219-221
83. Ball D.K., et al. Characterization of 16- to 20-kilodalton (kDa) connective tissue growth factors (CTGFs) and demonstration of proteolytic activity for 38-kDa CTGF in pig uterine luminal flushings. Biol. Reprod. 59 (1998) 828-835
84. Tan K., et al. Crystal structure of the TSP-1 type 1 repeats: a novel layered fold and its biological implication. J. Cell Biol. 159 (2002) 373-382
85. Paakkonen K., et al. Solution structures of the first and fourth TSR domains of F-spondin. Proteins 64 (2006) 665-672
86. Lazar N., et al. Domain-specific CCN3 antibodies as unique tools for structural and functional studies. J. Cell Commun. Sig. 1 (2007) 91-102
87. Subramaniam M.M., et al. Expression of CCN3 protein in human Wilms' tumors: immunohistochemical detection of CCN3 variants using domain-specific antibodies. Virchows Arch. 452 (2008) 33-39
88. McDonald N.Q., and Hendrickson W.A. A structural superfamily of growth factors containing a cystine knot motif. Cell 73 (1993) 421-424
89. Schlunegger M.P., and Grutter M.G. Refined crystal structure of human transforming growth factor beta 2 at 1.95 Å resolution. J. Mol. Biol. 231 (1993) 445-458
90. Perbal B., et al. The C-terminal domain of the regulatory protein NOVH is sufficient to promote interaction with fibulin 1C: a clue for a role of NOVH in cell-adhesion signaling. Proc. Natl. Acad. Sci. U. S. A. 96 (1999) 869-874
91. Cardin A.D., and Weintraub H.J. Molecular modeling of protein-glycosaminoglycan interactions. Arteriosclerosis 9 (1989) 21-32
92. Sakamoto K., et al. The nephroblastoma overexpressed gene (NOV/ccn3) protein associates with Notch1 extracellular domain and inhibits myoblast differentiation via Notch signaling pathway. J. Biol. Chem. 277 (2002) 29399-29405
93. r 10,000 forms of connective tissue growth factor. J. Biol. Chem. 272 (1997) 20275-20282
94. Planque N., et al. Nuclear addressing provides a clue for the transforming activity of amino-truncated CCN3 proteins. J. Cell. Biochem. 99 (2006) 105-116
95. Rider C.C. Heparin/heparan sulphate binding in the TGF-beta cytokine superfamily. Biochem. Soc. Trans. 34 (2006) 458-460
96. Isaacs N.W. Cystine knots. Curr. Opin. Struct. Biol. 5 (1995) 391-395
97. Lyon M., et al. The interaction of the transforming growth factor-betas with heparin/heparan sulfate is isoform-specific. J. Biol. Chem. 272 (1997) 18000-18006
98. Kelley L.A., et al. Enhanced genome annotation using structural profiles in the program 3D-PSSM. J. Mol. Biol. 299 (2000) 499-520
99. Bennett-Lovsey R.M., et al. Exploring the extremes of sequence/structure space with ensemble fold recognition in the program Phyre. Proteins 70 (2008) 611-625
100. Greenwald J., et al. The BMP7/ActRII extracellular domain complex provides new insights into the cooperative nature of receptor assembly. Mol. Cell 11 (2003) 605-617
101. Hart P.J., et al. Crystal structure of the human TbetaR2 ectodomain-TGF-beta3 complex. Nat. Struct. Biol. 9 (2002) 203-208
102. Hinck A.P., et al. Transforming growth factor beta 1: three-dimensional structure in solution and comparison with the X-ray structure of transforming growth factor beta 2. Biochemistry 35 (1996) 8517-8534
103. Kawaki M., et al. Cooperative regulation of chondrocyte differentiation by CCN2 and CCN3 revealed by a comprehensive analysis of the CCN family proteins in cartilage. J. Bone Miner. Res. (2008). www.jbmronline.org 10.1359/jbmr.080615
104. Chen N., et al. Identification of a novel integrin alphavbeta3 binding site in CCN1 (CYR61) critical for pro-angiogenic activities in vascular endothelial cells. J. Biol. Chem. 279 (2004) 44166-44176
105. Leu S.J., et al. Identification of a novel integrin alpha 6 beta 1 binding site in the angiogenic inducer CCN1 (CYR61). J. Biol. Chem. 278 (2003) 33801-33808
106. Leu S.J., et al. Targeted mutagenesis of the angiogenic protein CCN1 (CYR61). Selective inactivation of integrin alpha6beta1-heparan sulfate proteoglycan coreceptor-mediated cellular functions. J. Biol. Chem. 279 (2004) 44177-44187
107. Notredame C., et al. T-Coffee: A novel method for fast and accurate multiple sequence alignment. J. Mol. Biol. 302 (2000) 205-217